Monograph Details
|
|
Central Nervous System
> Psychosis
|
|
ZYPREXA ZYDIS |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Thienobenzodiazepine. |
| Generic Name |
|
Olanzapine 5mg, 10mg, 15mg, 20mg; orally-disintegrating tabs; contains phenylalanine. |
| Also |
• ZYPREXA
• ZYPREXA INTRAMUSCULAR
|
| Indications |
|
Schizophrenia. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 5–10mg once daily; increase to 10mg once daily within several days, adjust by 5mg/day at intervals of 1 week; max 20mg/day. Debilitated, risk of hypotension, slow metabolizers, or sensitive to olanzapine: initially 5mg once daily; increase cautiously. Zydis: Dissolve in mouth and swallow with or without fluids. |
| Precautions |
|
Diabetes risk factors (obtain baseline fasting blood sugar). Monitor for hyperglycemia. Cardio- or cerebrovascular disease. Hypovolemia. Dehydration. Seizures. Hepatic impairment (monitor ALT/AST). GI or GU obstruction. Narrow angle glaucoma. History of paralytic ileus or breast cancer. Exposure to extreme heat. Reevaluate periodically. Dysphagia. Suicidal ideation. Write Rx for smallest practical amount. Elderly (esp. with dementia). Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Orthostatic hypotension with antihypertensives, alcohol, benzodiazepines, others. Avoid alcohol. Caution with other CNS drugs, drugs that lower seizure threshold, anticholinergics, and with hepatotoxic agents. May antagonize levodopa, dopamine agonists. May be antagonized by rifampin, omeprazole, carbamazepine, others that induce CYP1A2 or glucuronyl transferase. May be potentiated by fluvoxamine, others that inhibit CYP1A2. Smokers may have increased metabolism. |
| Adverse Reactions |
|
Somnolence, dizziness, constipation, weight gain, personality disorder, akathisia, asthenia, rhinitis, postural hypotension, tachycardia, headache, fever, abdominal pain, cough, pharyngitis, nervousness, joint pain, peripheral edema, hyperglycemia, tardive dyskinesia, worsening of parkinsonian symptoms, neuroleptic malignant syndrome, hyperprolactinemia, increased ALT; others. |
| How Supplied |
Tabs—30, 60, 1000
Zydis—30
Vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
